Familial Mediterranean Fever in Siblings

2012 ◽  
Vol 39 (11) ◽  
pp. 2170-2174
Author(s):  
Z. BIRSIN ÖZÇAKAR ◽  
BEYZA DOGANAY ERDOGAN ◽  
ATILLA H. ELHAN ◽  
FATOŞ YALÇINKAYA

Objective.Genetic and environmental factors have been implicated in disease severity and development of amyloidosis in familial Mediterranean fever (FMF). We investigated similarities in clinical characteristics, disease severity, and treatment response within siblings with FMF.Methods.The study group consisted of 2 or more siblings who were followed in our center with the diagnosis of FMF. Siblings were evaluated for demographic data, clinical and laboratory disease features, genetic analysis of MEFV mutations, and disease severity score. The intraclass correlation coefficient (ICC), which can be interpreted as the expected correlation between 2 siblings, was used to reflect within-family similarity.Results.The study included 67 pediatric patients from 31 different families. When we investigated the similarity of siblings after adjusting for genetic effects, we found very low ICC with p > 0.05 in the majority of clinical features, disease severity, and colchicine dosages. However, age at disease onset, age at onset of therapy, attack-free acute-phase reactant levels, and presence of amyloidosis were found to be similar within siblings (relatively high ICC with p < 0.05).Conclusion.Siblings with FMF had different clinical findings and disease severity. They had similar amyloidogenic potential, proven by both similar presence of amyloid and increased levels of acute-phase reactants between attacks. Our findings strongly support that genetic factors may be more dominant in the development of amyloidosis.

2021 ◽  
Vol 9 ◽  
Author(s):  
Ahmet Omma ◽  
Berkan Armaǧan ◽  
Serdar Can Güven ◽  
Sevinç Can Sandıkçı ◽  
Seda Çolak ◽  
...  

Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory diseases.Objectives: This study aimed to evaluate serum endocan levels in FMF patients according to whether attack and colchicine resistance or not and also compare them with classical acute phase reactants.Methods: In this single-center and cross-sectional study, a total of 111 FMF patients and 60 healthy individuals were enrolled. All patients' basic demographic and clinical data were recorded and blood samples were collected.Results: A total of 46 (41.4%) FMF patients had colchicine resistance. In comparison to the FMF patients according to colchicine response, colchicine resistance patients had a significantly higher median (IQR) endocan levels than colchicine responsive patients [36.98 ng/ml (97.41) vs. 13.57 ng/ml (27.87), p = 0.007], but there were no differences between in terms of median ESR and CRP levels. Inversely, serum endocan levels were similar during an attack and attack-free period in FMF patients, although ESR and CRP levels were significantly different. Interestingly, the highest serum endocan levels were in the control group.Conclusion: In conclusion, serum endocan levels were higher in colchicine resistance than colchicine responsive patients, but attack state had no effect on serum endocan levels in our study. Unlike ESR and CRP, serum endocan may be a novel biomarker for detection of colchicine resistance and distinguish the FMF attacks.


2010 ◽  
Vol 38 (3) ◽  
pp. 516-518 ◽  
Author(s):  
SEZA ÖZEN ◽  
YELDA BILGINER ◽  
NURAY AKTAY AYAZ ◽  
MERAL CALGUNERI

Objective.Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the standard therapy for preventing attacks and suppressing inflammation, 5%–10% of compliant patients are colchicine-resistant. We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy.Methods.Five children and an adult patient (3 female, 3 male) who were experiencing at least 2 attacks per month and had consistently elevated C-reactive protein levels despite regular colchicine therapy were given either etanercept or anakinra.Results.Although etanercept lowered the number of attacks (from 3–4 attacks per month to 2 attacks per month), attacks still recurred and acute-phase reactants remained high in 2 patients; thus etanercept was considered ineffective. All 4 patients were switched to anakinra. In 2 patients anakinra completely resolved clinical and laboratory findings. The other 4 patients have been switched to anakinra recently; to date anakinra has reduced the number of attacks (to < 1 per month) and lowered the levels of acute-phase reactants.Conclusion.In this small series, anakinra was succesful in suppressing inflammation and decreasing the number of attacks in FMF. This may be explained by the role of pyrin in the regulation of IL-1ß activation.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1214.1-1215
Author(s):  
S. Ugurlu ◽  
B. H. Egeli ◽  
O. Selvi ◽  
B. Ergezen ◽  
A. Hadzalic ◽  
...  

Background:Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease characterized by recurrent, self-remitting attacks of fever, serositis, arthritis, and erysipelas-like erythema. Canakinumab is an Interleukin-1β inhibitor that is shown to be effective and safe in treating colchicine resistant FMF patients.Objectives:The main objective of this study is to present the single tertiary center experience of adult FMF patients who received Canakinumab.Methods:The study is a retrospective analysis conducted at a tertiary rheumatology center experienced in FMF. The patients who had a clinical diagnosis of FMF and who were treated with at least a single subcutaneous injection of canakinumab were included. Patients with amyloidosis and pregnancy were excluded. In order to evaluate the disease status, acute phase reactants and patient-reported disease severity visual analog scale (VAS) scores were analyzed. Acute phase reactants were evaluated during attack-free periods. The VAS score was reported on a scale of 0-10, 10 meaning the disease at its most severe form, and 0 meaning the least.Results:Fifty-two patients (21 male, 31 female) with the mean age of 35.88±12.4 years, were included in this study. The presenting signs and symptoms of the patients are shown in Figure 1. The mean age of initial symptoms and diagnosis were 12.84±10.06 and 20.39±12.35 years in respective order. The treatment information of the patients before and during Canakinumab injections was shown in Table 1. The mean Erythrocyte Sedimentation Rate (ESR) decreased from 25.31±20.64 to 11.52±9.78 mm/hour. The mean C-reactive Protein (CRP) decreased from 28.18±47.04 to 2.02±2.31 mg/L (both p<0.0001). The mean VAS score decreased from 8.04±1.9 to 1.4±1.73 (p<0.0001). Canakinumab treatment was terminated in 33 patients, 22 of which was due to successful remission. The termination of the treatment was because of pregnancy or will of pregnancy in 4 patients, inadequate treatment response 3 patients, treatment noncompliance in 2 patients, chronic hepatitis C related cirrhosis in 1 patient, and change to a different biologic agent in 1 patient. The only side effect experienced was hallucinations in one patient who was already under remission.Figure 1.The Presenting Signs and Symptoms of the PatientsTable 1.The Treatment Information of the PatientsInitial Mean Daily Colchicine Dose, mg (mean± standard deviation)1.68±0.46Mean Daily Colchicine Dose before Canakinumab Treatment, mg1.63±0.6The Mean Injection Number, n17.5±17.8Canakinumab Treatment Indication, n (%) Inadequate Response to Previous Treatment38 (73.08) Side Effect to Previous Treatment8 (15.38) Poly Arteritis Nodosa2 (3.85) Recurrent Pericarditis1 (1.92) CNS Vasculitis2 (3.85) Poor Anakinra Treatment Adherence1 (1.92) FMF Encephalopathy1 (1.92)Conclusion:Canakinumab seems effective in controlling the subclinical inflammation and raising the quality of life of the patient. It has a favorable side effect profile. According to our single-center, real-life data, Canakinumab can be used as an alternative treatment method in colchicine resistant patients.Disclosure of Interests:None declared


2015 ◽  
Vol 13 (Suppl 1) ◽  
pp. P139 ◽  
Author(s):  
R Mercan ◽  
B Bitik ◽  
R Eren ◽  
B Dumludag ◽  
A Turan ◽  
...  

2021 ◽  
Vol 48 (1) ◽  
Author(s):  
Yomna Farag ◽  
Samia Salah ◽  
Hanan Tawfik ◽  
Mai Hamed ◽  
Huda Marzouk

Abstract Background Familial Mediterranean fever (FMF) is an autosomal recessive disorder affecting people in the region of the Mediterranean Sea. It is usually associated with mutation in Mediterranean fever (MEFV) gene that encodes the pyrin protein, which affects the innate inflammatory response. Toll-like receptors (TLR) are a family of pattern recognition receptors that recognize pathogenic microbes and activate antimicrobial defense mechanisms. Toll-like receptor 4 (TLR-4) is concerned with recognition of gram-negative organisms. There is growing clinical evidence suggesting a role for expression of TLRs in the immune pathogenesis of FMF. Thus, the aim of the current study was to evaluate the presence of TLR-4 (p.Asp299Gly) and TLR-4 (p.Thr399Ile) gene variants in association with Egyptian children having FMF, furthermore, its effect on disease course and severity. Results Seventy Egyptian children diagnosed as having FMF, together with 50 age and gender-matched controls were enrolled in the study. The TLR-4 (p.Asp299Gly) and (Thr399Ile) gene variants were determined by PCR-RFLP analysis for all studied patients and controls. TLR-4 p.Asp299Gly gene variant was detected in 1 (1.4%) of the patients and p.Thr399Ile gene variant was detected in 2 (2%). None of the controls had any of the two tested gene variants. All found variations were heterozygous. We could not find a statistically significant association with disease severity in cases with or without TLR-4 gene variants (P = 0.568). Patients with M694V gene mutation showed a higher disease severity (P = 0.035). Conclusion TLR-4 (p.Asp299Gly) and (p.Thr399Ile) gene variants were not found to have a link with the occurrence, the clinical picture of FMF, its severity, and response to colchicine treatment in Egyptian children. M694V gene mutation seems to be associated with higher disease severity. Further larger studies are needed to verify these results.


Author(s):  
Joseph Press ◽  
Yael Shinar ◽  
Pnina Langevitz ◽  
Avi Livneh ◽  
Mordehai Pras ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document